<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117284</url>
  </required_header>
  <id_info>
    <org_study_id>20130344</org_study_id>
    <nct_id>NCT02117284</nct_id>
  </id_info>
  <brief_title>Rubidium Elution System Performance Testing</brief_title>
  <acronym>REST-PET</acronym>
  <official_title>Rubidium Elution System Performance Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jubilant DraxImage Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rubidium is a newly approved nuclear medicine imaging drug or 'tracer' used to look at blood
      flow in the heart. This tracer is given using a special pump called an 'elution system' which
      is considered investigational. This means the device is not yet approved by Health Canada for
      general use, but it has been approved for use in this study. It has been used routinely in
      this hospital since 2010.

      The purpose of this study is to confirm proper operation of the pump. It may also help
      identify areas for future improvement. The study data may be used for safety reporting to the
      Ministry of Health or to Health Canada. The study will enroll 2,400 patients in 6 hospitals
      across Canada. The University of Ottawa Heart Institute (UOHI) will enroll up to 1,200
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives: To evaluate performance of the rubidium elution systems (RBES)
      manufactured by Jubilant DraxImage (JDI); specifically using the constant-activity-rate
      intravenous infusion of rubidium-82 from the Ruby-Fillâ„¢ generator for diagnostic imaging of
      myocardial perfusion with PET. The V3 elution system is more highly automated, therefore
      requiring fewer manual performance checks.

      Hypotheses:

        1. Performance: system operation using constant-activity infusion is adequate to achieve:

             1. elution activity (82Rb) bias &lt; 5% (V2 and V3)

             2. elution activity (82Rb) imprecision &lt; 5% (V2 and V3)

             3. elution time interval (30 s) bias &lt; 5% (V2 only)

             4. elution success-rate reliability &gt; 98% (failure-rate &lt; 2%) (V2 and V3)

        2. Daily Quality Assurance: testing procedures are adequate to document:

             1. Automated generator yield (82Rb) imprecision &lt; 10% (V2 only)

             2. Automated generator breakthrough (82Sr, 85Sr) imprecision &lt; 10% (V2 and V3)

             3. Manual generator yield (82Rb) imprecision &lt; 10% (V2 only)

             4. Manual generator breakthrough (82Sr, 85Sr) imprecision &lt; 10% (V2 only)

        3. Monthly Quality Assurance: testing procedures are adequate to document:

             1. Dose calibrator non-linearity &lt; 1% (V2 and V3)

             2. Dose calibrator constancy &gt; 99% (instability &lt; 1%) (V2 only)

             3. Dose calibrator bias &lt; 10% (V2 only)

             4. Peristaltic pump calibration bias &lt; 10% (V2 only) 2.2 Secondary Objectives: To
                evaluate the user documentation and training reliability for:

        4. Installation of the Ruby-Fill generator and Ruby-Set tubing (V2 and V3)

        5. Trouble-shooting and repair of system errors (e.g. high-pressure) (V2 and V3) 2.3
           Tertiary Objective: To evaluate patient demographics or health status effects on system
           performance
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>System Performance:</measure>
    <time_frame>1 year</time_frame>
    <description>System operation using constant-activity infusion is adequate to achieve:
elution activity (82Rb) bias &lt; 5% (V2 and V3)
elution activity (82Rb) imprecision &lt; 5% (V2 and V3)
elution time interval (30 s) bias &lt; 5% (V2 only)
elution success-rate reliability &gt; 98% (failure-rate &lt; 2%) (V2 and V3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Quality Assurance:</measure>
    <time_frame>1 year</time_frame>
    <description>System testing procedures are adequate to document:
Automated generator yield (82Rb) imprecision &lt; 10% (V2 only)
Automated generator breakthrough (82Sr, 85Sr) imprecision &lt; 10% (V2 and V3)
Manual generator yield (82Rb) imprecision &lt; 10% (V2 only)
Manual generator breakthrough (82Sr, 85Sr) imprecision &lt; 10% (V2 only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly Quality Assurance</measure>
    <time_frame>1 year</time_frame>
    <description>System testing procedures are adequate to document:
Dose calibrator non-linearity &lt; 1% (V2 and V3)
Dose calibrator constancy &gt; 99% (instability &lt; 1%) (V2 only)
Dose calibrator bias &lt; 10% (V2 only)
Peristaltic pump calibration bias &lt; 10% (V2 only)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>User documentation</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the user documentation and training reliability for:
Installation of the Ruby-Fill generator and Ruby-Set tubing (V2 and V3)
Trouble-shooting and repair of system errors (e.g. high-pressure) (V2 and V3)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">7500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Coronary artery disease</arm_group_label>
    <description>All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients present to participating nuclear imaging facilities for diagnosis of CAD
        and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the
        clinical indications listed in the approved Ruby-Fill product monograph.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients presenting to participating nuclear imaging facilities with Rb-82 PET for
        diagnosis and/or risk stratification for CAD (as listed in the approved Ruby-Fill product
        monograph), who are at least 18 years of age and have given informed consent or those who
        have consented to and are currently participating in an Ottawa Health Science Network
        Research Ethics Board (OHSN-REB) approved protocol utilizing Rb-82 PET will be eligible.

        Exclusion Criteria:

          -  Patients with contraindications to stress radionuclide imaging including:

          -  Severe reactive airway disease;

          -  &lt;3 days post myocardial infarction (MI) or acute coronary syndrome (ACS) presentation;

          -  Unstable crescendo angina;

          -  High grade atrioventricular (AV) block;

          -  Severe claustrophobia;

          -  Patients who are or may be pregnant will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob S Beanlands, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda M Garrard, BScN</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>14192</phone_ext>
    <email>lgarrard@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert A deKemp, PhD</last_name>
    <phone>613-696-7374</phone>
    <email>radekemp@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Healath Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Gulenchyn, MD</last_name>
      <email>gulenkar@HHSC.CA</email>
    </contact>
    <investigator>
      <last_name>Karen Gulenchyn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Marriott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna MacDonald, RN</last_name>
    </contact>
    <investigator>
      <last_name>Gerald Wisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda M Garrard, BScN</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>14192</phone_ext>
      <email>lgarrard@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Robert A deKemp, PhD</last_name>
      <phone>613-696-7374</phone>
      <email>radekemp@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Robert A deKemp, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M Iwanochko, MD</last_name>
      <email>robertmark.iwanochko@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Robert M Iwanochko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Klein R, Adler A, Beanlands RS, Dekemp RA. Precision-controlled elution of a 82Sr/82Rb generator for cardiac perfusion imaging with positron emission tomography. Phys Med Biol. 2007 Feb 7;52(3):659-73. Epub 2007 Jan 11.</citation>
    <PMID>17228112</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Rob Beanlands</investigator_full_name>
    <investigator_title>Chief, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>positron emission tomography (PET)</keyword>
  <keyword>Rubidium-82</keyword>
  <keyword>myocardial perfusion imaging</keyword>
  <keyword>automated elution system</keyword>
  <keyword>controlled radioactivity delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

